Market Tracker

02/20 3:38am ET

Enzo Biochem Inc (NYSE:ENZ)

6.84
Delayed Data
As of Feb 17
 +0.19 / +2.86%
Today’s Change
4.00
Today|||52-Week Range
7.51
-1.44%
Year-to-Date
Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss
Feb 10 / Zacks.com - Paid Partner Content
GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1
Feb 08 / Zacks.com - Paid Partner Content
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise
Feb 09 / Zacks.com - Paid Partner Content
Mallinckrodt (MNK) Tops on Earnings in Transition Quarter
Feb 07 / Zacks.com - Paid Partner Content
Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View
Feb 09 / Zacks.com - Paid Partner Content
ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib
Feb 07 / Zacks.com - Paid Partner Content
Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.
Feb 08 / Zacks.com - Paid Partner Content
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3
Feb 06 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close6.65
Today’s open6.71
Day’s range6.59 - 6.85
Volume181,757
Average volume (3 months)170,134
Market cap$316.6M
Dividend yield--
Data as of 4:02pm ET, 02/17/2017

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+20.00%
Earnings growth (next 5 years)--
Revenue growth (last year)+5.30%
P/E ratio8.1
Price/Sales3.16
Price/Book3.53

Competitors

 Today’s
change
Today’s
% change
RDNTRadNet Inc-0.05-0.80%
NVTAInvitae Corp-0.07-0.73%
PTIProteostasis Therape...+0.38+2.39%
CCMConcord Medical Serv...+0.18+3.83%
Data as of 4:03pm ET, 02/17/2017

Financials

Next reporting dateMarch 14, 2017
EPS forecast (this quarter)-$0.04
Annual revenue (last year)$102.8M
Annual profit (last year)$45.3M
Net profit margin44.06%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, Chief Executive Officer &
Secretary
Elazar Rabbani
President, CFO, Treasurer &
Class II Director
Barry W. Weiner
Corporate headquarters
New York, New York

Forecasts